Lipoprotein(a) concentration and molecular weight of apolipoprotein(a) in patients with cerebrovascular disease and diabetes mellitus

Thrombosis Research

Volumn 87, Issue 6, 1997, Pages 527-538

  Saito, Tetsuo ^a   Ookubo, Ryuichi ^b   Kuriyama, Masaru ^b   Sano, Ryuichi ^c   Ichinose, Akitada ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c Yonezawa City Hospital   (Japan)

Author keywords

Apolipoprotein(a); Atherosclerosis; Kringle Domain; Lipoprotein(a); Thrombosis

Indexed keywords

APOLIPOPROTEIN A; INSULIN; LIPOPROTEIN A; ORAL ANTIDIABETIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; DIABETES MELLITUS; DIABETIC ANGIOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; OCCLUSIVE CEREBROVASCULAR DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK FACTOR; STROKE;

AGED; AGED, 80 AND OVER; APOLIPOPROTEINS; CEREBROVASCULAR DISORDERS; DIABETES MELLITUS; FEMALE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 0030796680     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00182-5     Document Type: Article

References (47)

1. BERG K. A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand. 59:1963;369-382.
2. UTERMANN G. The mysteries of lipoprotein(a). Science. 246:1989;904-910.
3. MILES L.A., PLOW E.F. An interloper into the fibrinolytic system? Thromb Haemost. 63:1990;331-335.
4. ARMSTRONG V.W., CREMER P., EBERLE E., MANKE A., SCHULZE F., WIELAND H., KRUEZER H., SEIDEL D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis. 62:1986;249-257.
5. MURAI A., MIYAHARA T., FUJIMOTO N., MATSUDA M., KAMEYAMA M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 59:1986;199-204.
6. RHOADS G.G., DAHLEN G., BERG K., MORTON N.E., DANNENBERG A.L. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 256:1986;2540-2544.
7. ZENKER G., KOLTRINGER P., BONE G., NIEDERKORN G., PFEIFFER K., JURGENS G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke. 17:1986;942-945.
8. JURGENS G., KOELTRINGER P. Lipoprotein(a) in ischemic cerebrovascular disease: a new approach to the assessment of risk for stroke. Neurology. 37:1987;513-515.
9. MCLEAN J.W., TOMLINSON J.E., KUANG W.-J., EATON D.L., CHEN E.Y., FLESS G.M., SCANU A.M., LAWN R.M. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 330:1987;132-137.
10. ICHINOSE A. Characterization of the apolipoprotein(a) gene. Biochem Biophys Res Commun. 209:1995;365-371.
11. VELHO G., ERLICH D., TURPIN E., NEEL D., COHEN D., FROGUEL P., PASSA P. Lipoprotein(a) in diabetic patients and normoglycemic relatives in familial NIDDM. Diabetes Care. 16:1993;742-747.
12. JENKINS A.J., BEST J.D. The role of lipoprotein(a) in the vascular complications of diabetes mellitus. J Intern Med. 237:1995;359-365.
13. RIDKER P.M., HENNECKENS C.H., STAMPFER M.J. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 270:1993;2195-2199.
14. RIDKER P.M., STAMPFER M.J., HENNECKENS C.H. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA. 273:1995;1269-1273.
15. Special report from the National Institute of Neurological Disorders and Stroke: Classification of cerebrovascular diseases III. Stroke 21, 637-676, 1990.
16. PEROMBELON Y.F.N., SOUTAR A.K., KNIGHT B.L. Variation in lipoprotein(a) concentration associated with different apolipoprotein(a) alleles. J Clin Invest. 93:1994;1481-1492.
17. HAFFNER S.M., TUTTLE K.R., RAINWATER D.L. Lack of change of lipoprotein(a) concentration with improved glycemic control in subjects with type II diabetes. Metabolism. 41:1992;116-120.
18. RAINWATER D.L., MaCLUER J.W., STERN M.P., WANDEBERG J.L., HAFFNER S.M. Effects of NIDDM on lipoprotein(a) concentration and apolipoprotein(a) size. Diabetes. 43:1994;942-946.
19. KLAUSEN I.C., SCHMIDT E.B., LERVANG H.H., GERDES L.U., DITZEL J., FAERGEMAN O. Normal lipoprotein(a) concentrations and apolipoprotein(a) isoforms in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest. 22:1992;538-541.
20. JURGENS G., TADDEI-PETERS W.C., KOLTRINGER P., PETER W., CHEN Q., GREILBERGER J., MACOMBER P.FF, BUTMAN B.T., STEAD A.G., RANSOM J.H. Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke. 26:1995;1841-1848.
21. UTERMANN G., MENZEL H.J., KRAFT H.G., DUBA H.C., KEMMLER H.G., SETITZ C. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 80:1987;458-565.
22. BOERWINKLE E., LEFFERT C.C., LIN J., LACKNER C., CHIESA G., HOBBS H.H. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 90:1992;52-60.
23. ICHINOSE A., KURIYAMA M. Detection of polymorphisms in the 5′-flanking region of the gene for apolipoprotein(a). Biochem Biophys Res Commun. 209:1995;372-378.
24. SUZUKI K., KURIYAMA M., SAITO T., ICHINOSE A. Plasma lipoprotein(a) levels and expression of the apolipoprotein(a) gene are dependent on the nucleotide polymorphisms in its 5′-flanking region. J Clin Invest. 99:1997;1276-1281.
25. BOERWINKLE E., MENZEL H.J., KRAFT H.G., UTERMANN G. Genetics of the quantitative Lp(a) trait. III. Contribution of the Lp(a) glycoprotein phenotypes to normal lipid variation Hum Genet. 82:1989;73-78.
26. LACKNER C., BOERWINKLE E., LEFFERT C.C., RAHMIG T., HOBBS H.H. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest. 87:1991;2153-2161.
27. KRAFT H.G., KOCHL S., MENZEL H.J., SANDHOLZER C., UTERMANN G. The apolipoprotein(a) gene: a transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum Genet. 90:1992;220-230.
28. PEDRO-BOTET J., SENTI M., NOGUES X., RUBIES-PRAT J., ROQUER J., D'OLHABERRIAGUE L., OLIVE J. Lipoprotein and apolipoprotein profile in men with ischemic stroke: Role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke. 23:1992;1556-1562.
29. NAGAYAMA M., SHINOHARA Y., NAGAYAMA T. Lipoprotein(a) and ischemic cerebrovascular disease in young adults. Stroke. 25:1994;74-78.
30. CHIANG A.-N., HU H.-H., SHAW G.-C., WONG W.-J. Lipid, apolipoprotein, and lipoprotein(a) levels in patients with different types of stroke. Med Sci Res. 22:1994;883-885.
31. HELLER F.R., JAMART J., HONORE P., DERUE G., NOVIK V., GALANTI L., PARFONRY A., HONDEKIJN J.C., BUYSSCHAERT M. Serum lipoprotein(a) in patients with diabetes mellitus. Diabetes Care. 16:1993;819-823.
32. MORISHITA E., ASAKURA H., JOKAJI H., SAITO M., UOTANI C., KUAMBASHIRI I., YAMAZAKI M., AOSHIMA K., HASHIMOTO T., MATSUDA T. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis. 120:1996;7-14.
33. WOLFFENBUTTEL B.H., SELS J.P., HEESEN B.J., MENHEERE P.P., KRUSEMAN A.C. Lipoprotein(A) levels and diabetes control [letter]. Diabetes Care. 15:1992;941.
34. BIRKELAND K.I., HANSSEN K.F., URDAL P., BERG K., VAALER S. A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in type 2 diabetes. J Int Med. 236:1994;305-313.
35. LIND H., NILSSON P., HOLTHUIS N., LINDHOLM L. Non-obese men with high lipoprotein(a) values - a cardiovascular risk group different from those with the metabolic syndrome? Scandinavian Journal of Clinical & Laboratory Investigation. 54:1994;177-183.
36. DUELL P.B., HAGEMENAS F., CONNOR W.E. The relationship between serum lipoprotein(a) and insulinemia in healthy nondiabetic adult men. Diabetes Care. 17:1994;1135-1140.
37. KREMPELER F., KOSTENR G.M., BOLZANO K., SANDHOFER F. Turnover of lipoprotein(a) in man. J Clin Invest. 65:1980;1483-1490.
38. RADER D.J., CAIN W., ZECH L.A., USHER D., BREWER H.B. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest. 91:1993;443-447.
39. RADER D.J., CAIN W., IKEWAKI K., TALLY G., ZECH L.A., USHER D., BREWER H.B. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to difference in Lp(a) catabolism but to differences in production rate. J Clin Invest. 93:1994;2758-2763.
40. GAUBATZ J.W., GHANEM K.I., GUEVARA J., NAVA M.L., PATSCH W., MORRISETT J.D. Polymorphic forms of human apolipoprotein(a): inheritance and relationship of their molecular weights to plasma levels of lipoprotein(a). J Lipid Res. 31:1990;603-613.
41. EDELBERG J.M., REILLY C.F., PIZZO S.V. The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a). J Biol Chem. 266:1991;7488-7493.
42. 2-antiplasmin. Biochem J. 286:1992;79-84.
43. ETINGIN O.R., HAJJAR D.P., HAJJAR K.A., HARPEL P.C., NACHMAN R.L. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem. 266:1991;2459-2465.
44. YAMAZAKI M., ASAKURA H., JOKAJI H., SAITO M., UOTANI C., KUAMBASHIRI I., MORISHITA E., AOSHIMA K., IKEDA T., MATSUDA T. Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome. Thromb Haemost. 71:1994;424-427.
45. SZCZEKLIK A., RADWAN J., KUBICKA A., LIBURA M., SACHA T., SWADZBA J., UNDAS A., SZCZEKLIK J., JODLWSKI J. Plasma fibrinolytic activity in healthy subjects with high and low lipoprotein(a) concentrations. Thromb Res. 66:1992;391-395.
46. AZNAR J., ESTELLES A., BRETO M., ESPANA F. Euglobulin clot lysis induced by tissue type plasminogen activator in subjects with increased levels and different isoforms of lipoprotein (a). Thromb Res. 72:1993;459-465.
47. FRANCESCHINI G., COFRANCESCO E., SAFA O., BOSCHETTI C., TREMOLI E., MUSSONI L., SIRTORI C.R., CORTELALLO M. Association of lipoprotein(a) with atherothrombotic events and fibrinolytic variables. A case-control study. Thromb Res. 78:1995;227-238.